Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, FVT

Symbility Solutions to Announce Q3 2017 Financial Results


TORONTO, Nov. 22, 2017 /PRNewswire/ - Symbility Solutions Inc. ("Symbility") (TSX.V: SY), a global software company focused on modernizing the insurance industry, confirmed that it will release its third quarter 2017 financial results after market close Wednesday, November 29, 2017. The press release, with accompanying financial information, will be posted on the Symbility's website at www.symbilitysolutions.com and on www.sedar.com.

Symbility Solutions Inc. (CNW Group/Symbility Solutions Inc.)

Symbility will host a live webcast and conference call Thursday, November 30, 2017, at 4 p.m. Eastern Time to discuss the financial results. All interested parties are invited to join the live webcast, which can be accessed at https://event.on24.com/wcc/r/1552199/A11D001ECBF38FA9A1C6EFD70F895B12. Participants may also join the conference call by dialing toll free (888) 231-8191 or (647) 427-7450 for international participants. A replay of the webcast will be available on Symbility's website. 

ABOUT SYMBILITY

Symbility (TSX.V: SY) believes in creating world-class experiences that simplify business and improve lives. With a history in modernizing insurance claims solutions for the property and health industries, Symbility has established itself as a partner that puts security, efficiency and customer experience first. Symbility PROPERTYtm brings smarter thinking to property insurance. Symbility HEALTHtm helps benefits professionals build their brands and businesses. Our strategic services team, Symbility INTERSECTtm empowers a variety of businesses with smarter mobile and IoT product development strategy, design thinking and engineering excellence. With our three segments pushing industries forward, Symbility proves that change for the better is entirely possible.  symbilitysolutions.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All trade names are the property of their respective owners.

SOURCE Symbility Solutions Inc.


These press releases may also interest you

18 avr 2024
The Montreal Daffodil Ball raises $1,474,785 to take on cancer
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIOŽ (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

More news about Health...


News published on and distributed by: